INTERNATIONAL MYELOMA SOCIETY

21st International Myeloma Society Annual Meeting

 

September 25-28, 2024 Rio de Janeiro
Close
N. Poster
Poster title
Applicant name
Status
  1-P Impact of Age and Frailty on Outcomes of Patients with Multiple Myeloma Receiving CAR T-Cell Therapies A single center experience Nadine Abdallah Received Received
  1-NSP Nursing Considerations for Young Adults with Multiple Myeloma, an Institutional Review Carrie Bellerive Received Received
  2-NSP Real world experience of talquetamab administration and the prevalence and management of associated dermatological toxicities Patrick Spencer Received Received
  4-NSP Patient perceptions when receiving Talquetamab for Triple Class Exposed Relapsed/ Refractory Myeloma: a thematic analysis Alex Greenwood Received Received
  6-P Differential Neutrophil Trajectory in Duffy-null Multiple Myeloma Patients Mimics Delayed Recovery Following BCMA CAR-T Zachary Avigan Received Received
  7-NSP Patient Reported Outcome Measures in Routine Haematology Cancer Care: A Scoping Review Suriya Kirkpatrick Received Received
  7-P Absolute lymphocyte count at Day 30 (not earlier) and early CRS predict delayed responses to teclistamab: Results from the US Myeloma Immunotherapy Consortium Rahul Banerjee Received Received
  8-NSP UK Pharmacist Prescribing Practice: Results of UKMS Pharmacy Survey Catherine Loughran Received Received
  9-P Digital Remote Patient Monitoring for Cytokine Release Syndrome in ABBV-383 Treatment: Methodology and Setup Brandy Menges Received Received
  10-NSP Improving diagnosis of myeloma in the UK: the power of multidisciplinary collaboration Suzanne Renwick Received Received
  11-NSP Predictive Factor for Higher Level of Preferences for Cure and Survival in Myeloma joseph tariman Received Received
  12-NSP The impact of an advanced clinical practitioner role in myeloma on service at a tertiary haematology centre: an exploratory case study analysis Jenna Tate Received Received
  13-P CERVINO: A phase 3, multicenter, randomized, open-label study of ABBV-383 compared with standard available therapies in patients with relapsed or refractory multiple myeloma (RRMM) Karin Angelucci - de Rooij Received Received
  14-P Efficacy and Safety of ABBV-383, a BCMA Bispecific Antibody, in Black Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of a Phase 1 Trial Karin Angelucci - de Rooij Received Received
  24-P Phase Ib Study Investigating the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Administration of ABBV-383 in Patients With Relapsed/Refractory Multiple Myeloma Karin Angelucci - de Rooij Received Received
  25-P Real-world outcomes of teclistamab for the treatment of relapsed/refractory multiple myeloma at UC San Diego Health: A single-institution experience Farid Ghamsari Received Received
  31-P Phase I study to evaluate cellular immunotherapy using CS-1 targeting autologous CAR T cells in patients with relapsed and refractory multiple myeloma (RRMM) Myo Htut Received Received
  34-P Real world Experience of Talquetamab in relapsed refractory Myeloma, First report from the IMWG consortium MURALI JANAKIRAM Received Received
  36-P BCMA after GPRC5D: Efficacy of BCMA-directed therapy on patients with relapsed/refractory multiple myeloma (RRMM) progressing after GPRC5D-directed therapy Laura Joiner Received Received
  37-P LONGITUDINAL SINGLE CELL MULTIOMIC ANALYSIS ALLOW THE IDENTIFICATION OF MECHANISM OF PERSISTENCE AND RESISTANCE TO CAR-T CELLS IN MM Paula Rodriguez-Marquez Received Received
  38-P Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated Analysis Eric Jurgens Received Received
  39-P CMV Reactivation During Treatment with Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma Eric Jurgens Received Received
  41-P Exploring MAGE-A1 as a therapeutic target in advanced Multiple Myeloma: Expression analysis and phase 1 clinical trial of MAGE-A1-directed TCR-1367 T cells Josefine Krüger Received Received
  45-P Idecabtagene vicleucel in patients with clinical high-risk early relapse multiple myeloma without front-line autologous stem cell transplantation: KarMMA-2 cohort 2B Stephanie Wolfe Received Received
  47-P Characteristics of Clinicopathological Features of 17 Patients Who had Relapsed Myeloma after Anti-BCMA CAR-T Therapy Pei Lin Received Received
  51-P iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito-Cel) With Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jill DeCarli Received Received
  52-P Efficacy and safety of idecabtagene vicleucel with lenalidomide maintenance versus lenalidomide maintenance alone in adult patients with newly diagnosed multiple myeloma who have suboptimal response to autologous stem cell transplantation: phase 3 KarMMa-9 trial Stephanie Wolfe Received Received
  53-P Early Absolute Lymphocyte Count after BCMA CAR-T as a Surrogate for CAR-T expansion, response, and Progression Free Survival in Multiple Myeloma Mateo Mejia Saldarriaga Received Received
  63-P Systematic literature review and meta-analysis of clinical trials of fourth line or higher treatment for relapsed/refractory multiple myeloma patients Eve Limbrick-Oldfield Received Received
  65-P Effectiveness and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: results of the French real-world RetrosTECtive study. Aurore PERROT Received Received
  68-P Developing Novel DKK1-A2 CAR-T Cell Therapy for Myeloma and Other Hematologic Malignancies Jianfei Qian Received Received
  72-P Health Care Resource Utilization and Economic Burden of Cytokine Release Syndrome Management in Patients With Multiple Myeloma Receiving CAR-T Cell and Bispecific Antibody Therapies Beth Stapleton Received Received
  73-P IDENTIFICATION AND VALIDATION OF FACTORS PROMOTING RESISTANCE TO CAR-T THERAPY IN MULTIPLE MYELOMA BY GENOME-WIDE CRISPR SCREENINGS Paula Rodriguez-Marquez Received Received
  75-P Development of a Quantitative Systems Pharmacology (QSP) model describing T-cell bispecific induced immune activation and Multiple Myeloma (MM) cell killing Cristina Santini Received Received
  78-P Prompt and Profound Responses with Talquetamab in Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma Another bridging therapy Hira Shaikh Received Received
  79-P Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma Hira Shaikh Received Received
  80-P Sequencing of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma Samuel Shewan Received Received
  87-P Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience Pablo Tenorio Feixas Received Received
  89-P Impact of COVID-19 on Outcomes With Teclistamab in the Phase 1/2 MajesTEC-1 Study in Patients With Relapsed/Refractory Multiple Myeloma Saad Usmani Received Received
  97-P Examining the impact of T-cell redirecting therapies in the treatment of ultra-high risk multiple myeloma and plasma cell leukemia Louis Williams Received Received
  102-P Ocular complications are common in patients with multiple myeloma receiving dexamethasone: Results of a cross-sectional patient survey Rahul Banerjee Received Received
  103-P Real World Data on Efficacy and Safety of Low-Dose Direct Oral Anticoagulants (DOACs) for Venous Thromboembolism (VTE) Prophylaxis in Newly Diagnosed Multiple Myeloma Diana Basali Received Received
  104-P Empowering Multiple Myeloma Patients: Impact of MMRF Education Programs and Results Of Patient Outcomes Veronica Bohorquez Received Received
  105-P PET/CT has prognostic significance for CAR T cell therapy in relapsed/refractory multiple myeloma Patrick Born Received Received
  117-P How do patients feel about how, when and where they get their treatments? A European survey of myeloma patients Eilidh Duncan Received Received
  119-P Treatment Outcomes of Primary vs. Referred Patients with Multiple Myeloma Receiving Talquetamab or Teclistamab Gina Fries Received Received
  120-P Diagnostic Value of Echocardiography in Multiple Myeloma Complicated with Cardiac Amyloidosis Chengcheng Fu Received Received
  124-P Trends in survival and causes of death in multiple myeloma: a single-institution experience Masaki Iino Received Received
  125-P Combination of geriatric assessment and clinical factors to predict the survival of elderly patients with myeloma Caroline Jin Received Received
  135-P Evaluating Racial Differences in the Systemic Impact of Monoclonal Protein in Multiple Myeloma Using Machine Learning Ehsan Malek Received Received
  136-P External Validation of a Machine Learning Model for Rapid Prediction of M-Spike Values in Multiple Myeloma Using the HealthTree Database Ehsan Malek Received Received
  137-P Optimizing Feature Selection for Large Language Models in AI-Assisted Clinical Assessment of Multiple Myeloma Ehsan Malek Received Received
  142-P Clinical epidemiologic features and disparities in access to diagnostic tools and novel therapies for MM Patients in Public and Private Health Care A Comparative Analysis of 2 Hospitals in Brazil. Danielle Lopes Received Received
  144-P Oral Symptom Assessment using Patient Reported Outcomes (PRO) for Relapsed Multiple Myeloma Patients treated with Talquetamab Rakesh Popat Received Received
  146-P Measuring symptom improvement in idiopathic multicentric Castleman disease: Protocol for a novel outcome measure Karthik Ramasamy Received Received
  147-P Central Nervous System Involvement in Multiple Myeloma Cases Reported at Instituto Nacional de Cancerología Miguel Angel Ramos Arrieta Received Received
  148-P Approach to Diagnosis and Management of multiple myeloma-related bone disease in Latin America, a GELAMM survey. Carolina Romero Received Received
  150-P Rapid whole-body PET/MRI with fat-suppressed T2-weighted imaging is superior to whole-body PET/MRI with diffusion-weighted imaging (DWI) in plasma cell disorders Timothy Schmidt Received Received
  151-P Dietary oleic acid influences the myeloma immune microenvironment and improves clinical outcomes Lilli Sophie Sester Received Received
  156-P Cryotherapy Prevents Hair Loss in Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation Robert Vescio Received Received
  161-P Gut microbiota differences among transplant ineligible patients with newly-diagnosed multiple myeloma treated with dara-len-dex Jehane Abed Received Received
  165-P Advanced circulating tumor DNA (ctDNA)Profiling: Enhancing Non-Invasive Detection and Characterization of Measurable Residual Disease (MRD) in Multiple Myeloma (MM) Natalia Buenache Received Received
  170-P Perspectives of single-center community hematologists/oncologists on minimal residual disease testing among patients with multiple myeloma Chloe Henry Received Received
  171-P DARATUMUMAB AS CONSOLIDATION THERAPY IN MULTIPLE MYELOMA PATIENTS IN VGPR/MRD POSITIVE AFTER FIRST LINE THERAPY: FINAL ANALYSIS OF THE MULTICENTRIC PHASE 2 STUDY DART4MM Alessandro Gozzetti Received Received
  174-P Outcomes of Patients with Newly Diagnosed Myeloma Cast Nephropathy in the Modern Era-A Retrospective Cohort Study Michael Hughes Received Received
  182-P IMPACT OF MINIMAL RESIDUAL DISEASE IN APHERESIS PRODUCT (aMRD) ASSESSED BY MULTIPARAMETRIC FLOW CYTOMETRY (MFC) IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS Borja Puertas Received Received
  183-P MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE (MGUS) LIKE PROFILE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS: CLINIC-BIOLOGICAL CHARACTERISTICS AND PROGNOSIS SIGNIFICANCE Borja Puertas Martínez Received Received
  184-P The utility of mass spectrometry in defining minimal residual disease in treated multiple myeloma patients Karthik Ramasamy Received Received
  187-P Prognostic implication of JAM-A expressing circulating tumor plasma cells in multiple myeloma Paula Tabares Received Received
  192-P T-cell receptor repertoire analysis of blood and bone marrow samples from multiple myeloma patients Chaitanya Acharya Received Received
  197-P Testing and Reporting of FISH Studies in Multiple Myeloma: Recommendations from the Cancer Genomics Consortium Myeloma Working Group for Best Practices Linda Baughn Received Received
  199-P Artificial Intelligence system to predict t(11,14) status in multiple myeloma patients by leveraging the correlation of plasma cell morphology and genetics David Bermejo-Peláez Received Received
  201-P Phosphatidylcholine Deactivates Cytotoxic CD8 T Cells Through UFMylation Mediated by Exosomal SerpinB9 in Multiple Myeloma Huihan Wang Received Received
  208-P Clonal evolution of lymphoid malignancy following the mutagenic impact of radiotherapy Benjamin Diamond Received Received
  211-P Clinical characteristics and prognostic values of 1p32.3 deletion in newly diagnosed multiple myeloma patients Chengcheng Fu Received Received
  216-P IRF2 Inhibition Impairs Cell Migration and Triggers Necroptosis in Multiple Myeloma Nahia Gomez Received Received
  220-P Profiling of immune checkpoints in the myeloma microenvironment Jana Jakubikova Received Received
  222-P Analysis of Normal Plasma Cell Distribution Across Distinct Age Cohorts Reveals Age Dependent Changes Diane Jelinek Received Received
  231-P Whole genome sequencing reveals lower APOBEC-mutational activity in multiple myeloma patients with African Ancestry compared with those of non-African Ancestry Kylee Maclachlan Received Received
  243-P Cytogenetics abnormalities in patients with newly diagnosed multiple myeloma analyzed by fluorescent in situ hybridization in Chilean patients. Carolina Romero Received Received
  248-P CRISPR-based functional genomics studies identify mechanisms of multiple myeloma (MM) cell response to vs. resistance against novel pharmacological mutant-specific KRAS inhibitors. Torsten Steinbrunn Received Received
  249-P Spatial transcriptomics unveils novel disease mechanisms associated with the microenvironment in Multiple Myeloma EMMA MUINOS-LOPEZ Received Received
  250-P ALTERATION OF THE m6A REGULATORY GENES, WITH THE SPECIAL IMPLICATION OF VIRMA, IS CRUCIAL FOR MULTIPLE MYELOMA DEVELOPMENT Estibaliz Urizar-Compains Received Received
  253-P Proteogenomic analysis of hyperdiploid multiple myeloma J. Erin Wiedmeier-Nutor Received Received
  262-P METABOLISM-ASSOCIATED GENES AS BIOMARKERS AND POTENTIAL THERAPEUTIC TARGETS FOR HYPERDIPLOID MULTIPLE MYELOMA Naroa Barrena Received Received
  268-P Defining the Rates of Cytokine Release Syndrome Associated with Talquetamab Step-up Doses. Issam Hamadeh Received Received
  270-P Alternative Splicing and Non-Homologous End Joining Pathways Are Vulnerabilities Associated With Loss of The Tumor Suppressor TENT5C in Myeloma Oumaima Jaouadi Received Received
  271-P YM155 exerts anti-myeloma effects via Myc/BBC3 signaling pathway in vitro Xianghong Jin Received Received
  272-P Dual targeting of the RAS-MAPK pathway as a personalized medicine approach in RASMut multiple myeloma Josefine Krüger Received Received
  273-P Inhibition of telomerase and the alternative lengthening telomere pathway induces cell death in Multiple Myeloma Sabine Mai Received Received
  276-P Vaccinating against mutated RAS in multiple myeloma: The phase I/II TG01 study Hanne Norseth Received Received
  277-P Impact of novel therapies on the overall survival of patients with multiple myeloma over the past two decades: a real-life single-center study. Esther Ortega Vida Received Received
  282-P Evaluation of the safety and efficacy of Denosumab in patients with multiple myeloma and severe renal impairment Evangelos Terpos Received Received
  283-P How to effectively administer belantamab mafodotin: Knowledge gained from the phase 1/2 BelaRd study in newly diagnosed transplant-ineligible patients with multiple myeloma Panagiota Tzani-Tzanopoulou Received Received
  285-P Identifying Anti-Viral Drugs to Sensitize and Re-Sensitize MM Cells to Chemotherapy Qiang Wang Received Received
  287-P HYPOALBUMINEMIA, A NEW RISK FACTOR FOR PROGRESSION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE? Elena Alejo Alonso Received Received
  288-P IMPACT OF THE ADDITION OF DARATUMUMAB TO THE FRONTLINE TREATMENT OF PATIENTS WITH AL AMYLOIDOSIS Elena Alejo Alonso Received Received
  290-P Ibrutinib plus rituximab versus ibrutinib monotherapy in patients with Waldenström macroglobulinemia: A pooled analysis of three prospective studies Jorge Castillo Received Received
  291-P Retrospective review of two cases of localized Iatrogenic Anakinra-type amyloidosis at The University of Texas MD Anderson Cancer Center Frances Cervoni-Curet Received Received
  297-P MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE: HOW SHOULD WE EVALUATE RESPONSE? EXPERIENCE IN A HOSPITAL COMPLEX. Amalia Domingo-González Received Received
  298-P MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE: DIAGNOSIS, TREATMENT AND PROGNOSIS IN A HOSPITAL COMPLEX. Amalia Domingo-González Received Received
  299-P Health-Related Quality of Life in Patients With Mayo Stage IV Light Chain (AL) Amyloidosis Treated With Birtamimab Plus Standard of Care: Results From the VITAL Trial Beatrice Vetter-Ceriotti Received Received
  300-P Evaluating the Efficacy and Safety of Limiting Dexamethasone in Newly Diagnosed AL Amyloidosis Compared to Conventional Dosing John Hanna Received Received
  306-P Open-Label Phase 1b Study to Evaluate the Safety and Efficacy of ABBV-383 Monotherapy in Patients With Relapsed or Refractory Light Chain Amyloidosis Karin Angelucci - de Rooij Received Received
  315-P Safety and Efficacy of Elranatamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series Pedro Vianna Received Received
  318-P A Real-World Comparison of First-Line Regimens in Transplant Ineligible Patients with Multiple Myeloma Nadine Abdallah Received Received
  321-P Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation Yosra Aljawai Received Received
  322-P Non-Cryopreserved Stem Cell Transplantation in Multiple Myeloma (MM) Patients: A Case Series Report Milton Aranha Received Received
  325-P In-class transition from parenteral bortezomib (V) to oral ixazomib in newly diagnosed multiple myeloma (NDMM): Updated 3-year PFS analysis of US MM-6 overall and by patient (pt) subgroups of interest Leon Bernal-Mizrachi Received Received
  326-P Phase 1b/2 trial of iberdomide in combination with daratumumab, dexamethasone /- carfilzomib to eliminate MRD after induction therapy and ASCT in NDMM Luciano Costa Received Received
  329-P Diagnostic challenges across the multiple myeloma pathway: perspectives of primary care physicians and orthopedic specialists Daniel Egbase Received Received
  341-P Response and Safety of Selinexor with VRD Regimen in Newly Diagnosed Multiple Myeloma (NDMM) with Extramedullary Disease (EMD): A Prospective, Open-Label, Multicenter, Phase 2 Study Yuanyuan Jin Received Received
  342-P Impact of achieving VGPR with RVD versus D-RVD induction therapy in newly diagnosed myeloma (NDMM) patients Nisha Joseph Received Received
  348-P Time to treatment initiation among Black and White older adults with multiple myeloma: A SEER-Medicare analysis Matthew LeBlanc Received Received
  352-P Impact of Obesity on Outcomes of Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Curtis Marcoux Received Received
  354-P Real-world comparison of progression free survival and time to next therapy endpoints in newly diagnosed patients with multiple myeloma Erin Mutterback Received Received
  355-P Melphalan vs Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as preparative regimen for newly diagnosed patients with Multiple Myeloma undergoing Autologous stem cell transplant. Swathi Namburi Received Received
  356-P Prognostic impact of t(11;14) in newly diagnosed patients with multiple myeloma Maria Gavriatopoulou Received Received
  357-P Outcomes of multiple myeloma patients with prior solid tumors undergoing an autologous transplant Oren Pasvolsky Received Received
  358-P Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation Oren Pasvolsky Received Received
  359-P Survival of patients with multiple myeloma treated with bortezomib-based triplets and autologous hematopoietic stem cell transplant as frontline in Latin America. Camila Peńa Received Received
  361-P Busulfan Plus Melphalan versus Melphalan Alone as Conditioning Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Long-Term Follow Up of a Randomized Phase III Trial Muzaffar Qazilbash Received Received
  367-P COST ANALYSIS FOR ADULT PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION Danielle Ovigli Lopes Received Received
  369-P OPTIMIZING THE ALCYONE TRIAL: EFFICACY OF DARATUMUMAB AND BORTEZOMIB MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS POST DARA-VMP INDUCTION, 1 YEAR ANALYSIS Luis-Esteban Tamariz-Amador Received Received
  375-P The significance and predictive performance of gait speed and grip strength in dynamic frailty assessment of newly diagnosed transplant non-eligible elderly patients with multiple myeloma HUA XUE Received Received
  376-P Gait speed, grip strength, and clinical outcomes in newly diagnosed transplant non-eligible elderly patients with multiple myeloma HUA XUE Received Received
  377-P Impact of weekly versus twice weekly bortezomib on rates of peripheral neuropathy in combination with lenalidomide, dexamethasone and daratumumab Irvin Yi Received Received
  380-P Carfilzomib Dosing in Multiple Myeloma: An International Survey of Oncologist Practices Rahul Banerjee Received Received
  382-P IXAZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REAL WORLD EVIDENCE EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM) Josip Batinic Received Received
  383-P Novel selinexor triplet and quadruplet regimens (SNd, SPEd, SBd, SDPd): Results from the Phase 1b/2 STOMP multiple myeloma trial Steve Mitchell Received Received
  385-P Management and outcomes in second and/or third relapse in patients with multiple myeloma in the real-life setting: EMMY study results. thomas chalopin Received Received
  386-P Effect of Prior Selinexor Exposure on Clinical Outcomes of Chimeric Antigen Receptor T-cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Descriptive Analysis Steve Mitchell Received Received
  390-P Carfilzomib Prescribing Patterns and Outcomes for Relapsed or Refractory Multiple Myeloma (RRMM): A Real-World Analysis Sharlene Dong Received Received
  394-P Selinexor combined with bortezomib, thalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients who have undergone severe treatment: a single-arm, multicenter, prospective study Jingsong He Received Received
  397-P Brazilian Single-Center Initial Experience and Safety of Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Mariana Kerbauy Received Received
  398-P Real-world Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone (IRd) in Asian Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Dionis Tan Received Received
  399-P Myeloid neoplasm post cytotoxic treatment (pCT-MN) in patients with myeloma- a UK single centre experience Charalampia KYRIAKOU Received Received
  408-P Survival Analysis of Selinexor-Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Real-World Exploratory Analysis Steve Mitchell Received Received
  410-P ALLG MM26/D1/AMN009 Novel Combinations for Orphan Myeloma (NORM) Platform Study Georgia McCaughan Received Received
  412-P Real World Outcomes with Elotuzumab-Based Therapies for Patients with Relapsed Refractory Multiple Myeloma (RRMM): A Mayo Clinic Experience Ricardo Parrondo Received Received
  414-P Real-World Treatment Patterns and Survival Outcomes of Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With a Selinexor-Containing Triplet-Based Regimen Steve Mitchell Received Received
  418-P Subcutaneous administration of isatuximab by an on-body delivery system (OBDS) in multiple myeloma patients: results of a nurse survey Nuria Sanchez Avello Received Received
  422-P Carfilzomib, Lenalidomide and Dexamethasone (KRD) therapy post autologous stem-cell transplantation (ASCT): real-world data in multiple myeloma patients eligible for second ASCT. Vilmante Vaitekenaite Received Received
  423-P Salvage Autologous PBSC Transplantation for tMDS and AML Leads to Remission and Long-Term Disease Control Robert Vescio Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
00:36
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

21st International Myeloma Society Annual Meeting

 

September 25-28, 2024 Rio de Janeiro
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 25/09/2024 TO 25/09/2024
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
Logo Cert